Is LTES or PFE a better dividend investment in 2026?

LTES currently yields 10000.00% with a 5% 5-year dividend growth rate. PFE yields 6.20% with 4.1% growth. The better choice depends on your goal: LTES offers higher current income.

What is the dividend yield difference between LTES and PFE?

LTES has a forward dividend yield of 10000.00% ($2.00/share annually). PFE yields 6.20% ($1.72/share annually). The yield gap is 9993.80 percentage points.

Home › Compare › LTES vs PFE

LTES vs PFE: Dividend Comparison 2026

LTES yields 10000.00% · PFE yields 6.20%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 LTES wins by $55137509079256512.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

LTES

● Live price

10000.00%

Share price

$0.02

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$55137509079256512.00M

Annual income

$54,073,795,673,722,890,000,000.00

Full LTES calculator →

PFE

Pfizer Inc.

● Live price

6.20%

Share price

$27.76

Annual div

$1.72

5Y div CAGR

13.2%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$51.1K

Annual income

$27,210.54

Full PFE calculator →

Portfolio growth — LTES vs PFE

📍 LTES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	LTES	PFE
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, LTES + PFE cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

LTES pays

PFE pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LTES

Annual income on $10K today (after 15% tax)

$850,000.00/yr

After 10yr DRIP, annual income (after tax)

$45,962,726,322,664,450,000,000.00/yr

PFE

Annual income on $10K today (after 15% tax)

$526.66/yr

After 10yr DRIP, annual income (after tax)

$23,128.96/yr

At 15% tax rate, LTES beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LTES + PFE for your $10,000?

LTES: 50%PFE: 50%

100% PFE50/50100% LTES

Portfolio after 10yr

$27568754539628256.00M

Annual income

$27,036,897,836,861,443,000,000.00/yr

Blended yield

98.07%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LTES

No analyst data

Altman Z

-103.7

Piotroski

0/9

PFE

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$27.50

-0.9% upside vs current

Range: $24.00 — $35.00

Altman Z

2.0

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LTES buys

PFE buys

No recent congressional trades found for LTES or PFE in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricLTESPFE

Forward yield	10000.00% ✓	6.20%
Annual dividend / share	$2.00 ✓	$1.72
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	13.2% ✓
Portfolio after 10y	$55137509079256512.00M ✓	$51.1K
Annual income after 10y	$54,073,795,673,722,890,000,000.00 ✓	$27,210.54
Total dividends collected	$55066727460582336.00M ✓	$60.1K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: LTES vs PFE ($10,000, DRIP)

Year	LTES Portfolio	LTES Income/yr	PFE Portfolio	PFE Income/yr	Gap
1← crossover	$1,010,700	$1,000,000.00	$9,161	$701.38	+$1.00M → LTES
2	$95,539,393	$94,457,943.93	$8,610	$859.79	+$95.53M → LTES
3	$8,447,007,736	$8,344,780,585.66	$8,366	$1,081.25	+$8447.00M → LTES
4	$698,565,746,383	$689,527,448,105.17	$8,483	$1,405.66	+$698565.74M → LTES
5	$54,040,711,670,213	$53,293,246,321,583.74	$9,084	$1,907.24	+$54040711.66M → LTES
6	$3,910,851,616,519,516	$3,853,028,055,032,387.00	$10,418	$2,732.78	+$3910851616.51M → LTES
7	$264,781,167,546,477,440	$260,596,556,316,801,570.00	$13,007	$4,193.56	+$264781167546.46M → LTES
8	$16,772,556,223,821,672,000	$16,489,240,374,546,942,000.00	$18,010	$7,005.87	+$16772556223821.65M → LTES
9	$994,124,678,068,810,000,000	$976,178,042,909,320,800,000.00	$28,216	$12,979.89	+$994124678068810.00M → LTES
10	$55,137,509,079,256,515,000,000	$54,073,795,673,722,890,000,000.00	$51,081	$27,210.54	+$55137509079256512.00M → LTES

LTES vs PFE: Complete Analysis 2026

LTES — Stock

Leet Technology Inc., through its subsidiaries, operates an eSports platform in Malaysia. It operates Matchroom.net, an eSports platform that offers gaming and digital entertainment services. The company also offers MAVERICK, a scalable and modular gaming platform solution. In addition, it offers information technology, mobile application development, and digital content publishing services. The company was formerly known as Blow & Drive Interlock Corporation and changed its name to Leet Technology Inc. in August 2021. Leet Technology Inc. is based in Petaling Jaya, Malaysia.

Full LTES Calculator →

PFE — Healthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

📬

Get this LTES vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LTES vs SCHD LTES vs JEPI LTES vs O LTES vs KO LTES vs MAIN LTES vs JNJ LTES vs MRK LTES vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.